Suchergebnisse - "Rifampin"

The clinical profile of patients with indeterminate Xpert rifampin resistance results in a single tertiary level institution.

Autoren: Tenorio BG Uayan DJ Lumunsad KF et al.

Quelle: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2025 Dec; Vol. 113 (4), pp. 117008. Date of Electronic Publication: 2025 Jul 26.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8305899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0070 (Electronic) Linking ISSN: 07328893 NLM ISO Abbreviation: Diagn Microbiol Infect Dis Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/pharmacology , Rifampin*/therapeutic use , Drug Resistance, Bacterial* , Mycobacterium tuberculosis*/drug effects , Mycobacterium tuberculosis*/genetics , Mycobacterium tuberculosis*/isolation & purification , Antitubercular Agents*/pharmacology , Antitubercular Agents*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Adult ; Tertiary Care Centers ; Aged ; Microbial Sensitivity Tests ; Retrospective Studies ; Molecular Diagnostic Techniques ; Young Adult ; Antibiotics, Antitubercular/pharmacology

Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series.

Autoren: Houwen JPA de Vries Schultink AHM Peters BJM et al.

Quelle: British journal of clinical pharmacology [Br J Clin Pharmacol] 2025 Dec; Vol. 91 (12), pp. 3542-3548. Date of Electronic Publication: 2025 Sep 30.

Publikationsart: Case Reports; Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/administration & dosage , Rifampin*/adverse effects , Rifampin*/pharmacology , Tacrolimus*/pharmacokinetics , Tacrolimus*/administration & dosage , Immunosuppressive Agents*/pharmacokinetics , Immunosuppressive Agents*/administration & dosage, Humans ; Drug Interactions ; Male ; Drug Monitoring/methods ; Middle Aged ; Female ; Adult ; Kidney Transplantation ; Drug Therapy, Combination

Fusobacterium nucleatum-targeted polymeric micelles disrupting biofilm-immune crosstalk for precision colorectal cancer immunotherapy.

Autoren: Wu T Zhang F Liu H et al.

Quelle: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Dec 10; Vol. 388 (Pt 2), pp. 114400. Date of Electronic Publication: 2025 Nov 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH-Schlagworte: Fusobacterium nucleatum*/drug effects , Fusobacterium nucleatum*/physiology , Biofilms*/drug effects , Colorectal Neoplasms*/therapy , Colorectal Neoplasms*/immunology , Colorectal Neoplasms*/drug therapy , Catechin*/analogs & derivatives , Catechin*/administration & dosage , Catechin*/chemistry , Catechin*/pharmacology , Rifampin*/administration & dosage , Rifampin*/pharmacology, Animals ; Micelles ; Humans ; Immunotherapy/methods ; Hydrogen-Ion Concentration ; Mice, Inbred BALB C ; Tumor Microenvironment/drug effects ; Mice ; Polymers/chemistry ; Cell Line, Tumor ; Female ; Polyethylene Glycols/chemistry ; Mice, Nude

Exosomal co-delivery of CircRNA-TRAPPC6B and rifampicin for enhanced immunotherapy against tuberculosis.

Autoren: Pi J Ma Y Wang W et al.

Quelle: International immunopharmacology [Int Immunopharmacol] 2025 Dec 10; Vol. 167, pp. 115696. Date of Electronic Publication: 2025 Oct 24.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/pharmacology , Rifampin*/administration & dosage , Rifampin*/therapeutic use , RNA, Circular*/administration & dosage , Exosomes*/metabolism , Mycobacterium tuberculosis*/drug effects , Mycobacterium tuberculosis*/immunology , Immunotherapy*/methods , Tuberculosis*/therapy , Tuberculosis*/immunology, Animals ; Mice ; Macrophages/immunology ; Macrophages/drug effects ; Macrophages/microbiology ; Humans ; Autophagy ; Mice, Inbred C57BL ; RAW 264.7 Cells

Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying 'breakpoints in brackets'.

Autoren: Boyd SE Wootton M Howe RA et al.

Quelle: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2025 Dec 02; Vol. 80 (12), pp. 3191-3193.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/therapeutic use , Rifampin*/pharmacology , Staphylococcal Infections*/drug therapy , Staphylococcal Infections*/microbiology , Staphylococcus aureus*/drug effects , Anti-Bacterial Agents*/therapeutic use , Anti-Bacterial Agents*/pharmacology, Humans ; Microbial Sensitivity Tests ; Drug Resistance, Bacterial

Model-based evaluation of the interaction between ritonavir-boosted atazanavir and rifampicin in Ugandan adults with HIV.

Autoren: Kengo A Resendiz-Galvan JE Najjemba L et al.

Quelle: British journal of clinical pharmacology [Br J Clin Pharmacol] 2025 Dec; Vol. 91 (12), pp. 3471-3481. Date of Electronic Publication: 2025 Aug 12.

Publikationsart: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article

Info zur Zeitschrift: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

MeSH-Schlagworte: Atazanavir Sulfate*/pharmacokinetics , Atazanavir Sulfate*/administration & dosage , Atazanavir Sulfate*/therapeutic use , Atazanavir Sulfate*/blood , HIV Infections*/drug therapy , HIV Infections*/blood , HIV Protease Inhibitors*/pharmacokinetics , HIV Protease Inhibitors*/administration & dosage , Models, Biological* , Rifampin*/pharmacokinetics , Rifampin*/administration & dosage , Rifampin*/pharmacology , Ritonavir*/pharmacokinetics , Ritonavir*/administration & dosage , Ritonavir*/therapeutic use, Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Drug Interactions ; Drug Therapy, Combination ; Leukocytes, Mononuclear/metabolism ; Tuberculosis/drug therapy ; Uganda

Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).

Autoren: Ruan QL Yang QL Ma CL et al.

Quelle: Emerging microbes & infections [Emerg Microbes Infect] 2025 Dec; Vol. 14 (1), pp. 2502010. Date of Electronic Publication: 2025 May 16.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101594885 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2222-1751 (Electronic) Linking ISSN: 22221751 NLM ISO Abbreviation: Emerg Microbes Infect Subsets: MEDLINE

MeSH-Schlagworte: Isoniazid*/administration & dosage , Isoniazid*/adverse effects , Isoniazid*/therapeutic use , Silicosis*/complications , Silicosis*/drug therapy , Rifampin*/analogs & derivatives , Rifampin*/administration & dosage , Rifampin*/adverse effects , Rifampin*/therapeutic use , Antitubercular Agents*/administration & dosage , Antitubercular Agents*/adverse effects , Antitubercular Agents*/therapeutic use , Tuberculosis*/prevention & control, Humans ; Middle Aged ; Male ; Female ; Pilot Projects ; Adult ; Aged ; Treatment Outcome ; China ; Young Adult ; Adolescent ; Drug Therapy, Combination ; East Asian People

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis.

Autoren: Seddon JA Achar J Malik AA et al.

Quelle: The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Dec; Vol. 25 (12), pp. e692-e704. Date of Electronic Publication: 2025 Jun 06.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE

MeSH-Schlagworte: Tuberculosis, Multidrug-Resistant*/drug therapy , Tuberculosis, Multidrug-Resistant*/prevention & control , Tuberculosis, Multidrug-Resistant*/transmission , Rifampin*/therapeutic use , Rifampin*/pharmacology , Antitubercular Agents*/therapeutic use, Humans ; Mycobacterium tuberculosis/drug effects ; HIV Infections/complications

Making post-exposure prophylaxis effective for leprosy elimination: Insights from a multi-country study on low-endemic settings.

Autoren: van der Putten Hadik SMT Fastenau A Schoenmakers A et al.

Quelle: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2025 Nov 18; Vol. 19 (11), pp. e0013716. Date of Electronic Publication: 2025 Nov 18 (Print Publication: 2025).

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE

MeSH-Schlagworte: Leprosy*/prevention & control , Leprosy*/epidemiology , Leprosy*/drug therapy , Post-Exposure Prophylaxis*/methods , Rifampin*/administration & dosage , Rifampin*/therapeutic use , Leprostatic Agents*/therapeutic use , Leprostatic Agents*/administration & dosage , Disease Eradication*, Humans ; Endemic Diseases/prevention & control ; Mycobacterium leprae/drug effects

Construction and clinical application of an innovative pharmacist-led service model for therapeutic drug monitoring in tuberculosis treatment: a pragmatic randomized controlled trial.

Autoren: Lei Q Wang H Dang L et al.

Quelle: BMC pulmonary medicine [BMC Pulm Med] 2025 Nov 18; Vol. 25 (1), pp. 529. Date of Electronic Publication: 2025 Nov 18.

Publikationsart: Journal Article; Randomized Controlled Trial; Pragmatic Clinical Trial

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 100968563 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2466 (Electronic) Linking ISSN: 14712466 NLM ISO Abbreviation: BMC Pulm Med Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/therapeutic use , Rifampin*/blood , Drug Monitoring*/methods , Antitubercular Agents*/therapeutic use , Antitubercular Agents*/blood , Isoniazid*/therapeutic use , Isoniazid*/blood , Pharmacists* , Tuberculosis*/drug therapy, Humans ; Female ; Male ; Adult ; Middle Aged

Analytical quality by design and measurement uncertainty in the development of discriminative dissolution method for pediatric fixed-dose combination dispersible tablets of isoniazid and rifampicin.

Autoren: Dos Santos MS do Nascimento DD Medeiros JJS et al.

Quelle: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2025 Nov 15; Vol. 265, pp. 116994. Date of Electronic Publication: 2025 May 27.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/chemistry , Rifampin*/analysis , Rifampin*/administration & dosage , Isoniazid*/chemistry , Isoniazid*/analysis , Isoniazid*/administration & dosage , Antitubercular Agents*/chemistry, Tablets/chemistry ; Uncertainty ; Solubility ; Monte Carlo Method ; Drug Combinations ; Drug Liberation ; Chemistry, Pharmaceutical/methods ; Quality Control ; Humans

Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical Trials.

Autoren: Moro RN Johnson JL Martinson N et al.

Quelle: The Journal of infectious diseases [J Infect Dis] 2025 Nov 14; Vol. 232 (5), pp. 1128-1138.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

MeSH-Schlagworte: Neutrophils* , Neutropenia*/chemically induced , Rifampin*/analogs & derivatives , Rifampin*/adverse effects , Rifampin*/therapeutic use , Rifampin*/administration & dosage , Tuberculosis*/drug therapy , Antitubercular Agents*/adverse effects , Antitubercular Agents*/therapeutic use , Antitubercular Agents*/administration & dosage, Humans ; Male ; Female ; Leukocyte Count ; Adult ; Middle Aged ; Black People ; Africa ; Young Adult

Acute pancreatic panniculitis in a domestic ferret (Mustela putorius furo): diagnostic insights and a potential drug-induced etiology.

Autoren: Giner J Villora J Juan-Sallés C et al.

Quelle: Veterinary research communications [Vet Res Commun] 2025 Nov 11; Vol. 50 (1), pp. 28. Date of Electronic Publication: 2025 Nov 11.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Springer Country of Publication: Switzerland NLM ID: 8100520 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7446 (Electronic) Linking ISSN: 01657380 NLM ISO Abbreviation: Vet Res Commun Subsets: MEDLINE

MeSH-Schlagworte: Ferrets* , Panniculitis*/veterinary , Panniculitis*/diagnosis , Panniculitis*/chemically induced , Panniculitis*/pathology , Clarithromycin*/adverse effects , Clarithromycin*/therapeutic use , Rifampin*/adverse effects , Rifampin*/therapeutic use , Anti-Bacterial Agents*/adverse effects , Pseudomonas Infections*/veterinary , Pseudomonas Infections*/diagnosis, Animals ; Male ; Fatal Outcome

Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova.

Autoren: Allel K Palmer T Abou Jaoude GJ et al.

Quelle: BMJ global health [BMJ Glob Health] 2025 Nov 08; Vol. 10 (11). Date of Electronic Publication: 2025 Nov 08.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101685275 Publication Model: Electronic Cited Medium: Print ISSN: 2059-7908 (Print) Linking ISSN: 20597908 NLM ISO Abbreviation: BMJ Glob Health Subsets: MEDLINE

MeSH-Schlagworte: Tuberculosis, Multidrug-Resistant*/drug therapy , Tuberculosis, Multidrug-Resistant*/economics , Rifampin*/therapeutic use , Rifampin*/administration & dosage , Antitubercular Agents*/economics , Antitubercular Agents*/administration & dosage , Antitubercular Agents*/therapeutic use, Humans ; Cost-Benefit Analysis ; Moldova ; Kazakhstan ; Quality-Adjusted Life Years ; Male ; Republic of Belarus ; Female ; Adult ; Administration, Oral ; Georgia (Republic) ; Middle Aged

Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa.

Autoren: Stadler JAM Kuhlin J Molloy SF et al.

Quelle: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2025 Nov 06; Vol. 81 (4), pp. e153-e162.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/therapeutic use , Rifampin*/pharmacology , HIV Infections*/epidemiology , HIV Infections*/complications , Tuberculosis, Multidrug-Resistant*/drug therapy , Tuberculosis, Multidrug-Resistant*/epidemiology , Antitubercular Agents*/administration & dosage , Antitubercular Agents*/therapeutic use, Humans ; South Africa/epidemiology ; Male ; Female ; Adult ; Prospective Studies ; Treatment Outcome ; Mycobacterium tuberculosis/drug effects ; Middle Aged ; Administration, Oral ; Prevalence ; Linezolid/therapeutic use ; Linezolid/administration & dosage ; Young Adult

Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China.

Autoren: Zou L Li Z Pan Q et al.

Quelle: Scientific reports [Sci Rep] 2025 Nov 05; Vol. 15 (1), pp. 38801. Date of Electronic Publication: 2025 Nov 05.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/therapeutic use , Rifampin*/pharmacology , Tuberculosis, Multidrug-Resistant*/epidemiology , Tuberculosis, Multidrug-Resistant*/drug therapy, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; China/epidemiology ; Comorbidity ; Prevalence ; Prognosis ; Retrospective Studies

Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study.

Autoren: Gelé T Atwine D Baudin E et al.

Körperschaften: Gelé T Atwine D Baudin E et al.

Quelle: The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2025 Nov 04; Vol. 80 (11), pp. 2945-2953.

Publikationsart: Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE

MeSH-Schlagworte: Rifampin*/pharmacokinetics , Rifampin*/administration & dosage , Isoniazid*/pharmacokinetics , Isoniazid*/administration & dosage , HIV Infections*/drug therapy , HIV Infections*/complications , Antitubercular Agents*/pharmacokinetics , Antitubercular Agents*/administration & dosage , Benzoxazines*/therapeutic use , Benzoxazines*/administration & dosage , Coinfection*/drug therapy , Tuberculosis*/drug therapy , Tuberculosis*/complications , Anti-HIV Agents*/therapeutic use , Anti-HIV Agents*/administration & dosage, Humans ; Male ; Female ; Adult ; Uganda ; Cyclopropanes ; Alkynes ; Middle Aged ; Young Adult ; Plasma/chemistry ; Drug Interactions

Rifapentine-based treatment of tuberculosis infection in Spanish adolescents.

Autoren: Noguera-Julian A Latre C Ruiz M et al.

Quelle: Enfermedades infecciosas y microbiologia clinica (English ed.) [Enferm Infecc Microbiol Clin (Engl Ed)] 2025 Nov; Vol. 43 (9), pp. 607-610.

Publikationsart: Journal Article; Case Reports

Info zur Zeitschrift: Publisher: Elsevier España Country of Publication: Spain NLM ID: 101777541 Publication Model: Print Cited Medium: Internet ISSN: 2529-993X (Electronic) Linking ISSN: 2529993X NLM ISO Abbreviation: Enferm Infecc Microbiol Clin (Engl Ed) Subsets: MEDLINE

MeSH-Schlagworte: Antibiotics, Antitubercular*/administration & dosage , Antibiotics, Antitubercular*/therapeutic use , Antitubercular Agents*/therapeutic use , Antitubercular Agents*/administration & dosage , Isoniazid*/therapeutic use , Isoniazid*/administration & dosage , Rifampin*/analogs & derivatives , Rifampin*/therapeutic use , Rifampin*/administration & dosage , Rifampin*/analogs & derivatives , Tuberculosis*/diagnosis , Tuberculosis*/drug therapy , Tuberculosis*/transmission, Adolescent ; Humans ; Contact Tracing ; Directly Observed Therapy ; Spain

Unveiling the molecular toxicity of Isoniazid and Rifampicin in tuberculosis therapy: emerging insights and therapeutic strategies.

Autoren: Shivaji P Prince SE

Quelle: Toxicology mechanisms and methods [Toxicol Mech Methods] 2025 Nov; Vol. 35 (9), pp. 1239-1270. Date of Electronic Publication: 2025 Sep 08.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 101134521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-6524 (Electronic) Linking ISSN: 15376516 NLM ISO Abbreviation: Toxicol Mech Methods Subsets: MEDLINE

MeSH-Schlagworte: Isoniazid*/toxicity , Isoniazid*/adverse effects , Rifampin*/toxicity , Rifampin*/adverse effects , Antitubercular Agents*/toxicity , Antitubercular Agents*/adverse effects , Tuberculosis*/drug therapy , Chemical and Drug Induced Liver Injury*/etiology , Chemical and Drug Induced Liver Injury*/metabolism , Chemical and Drug Induced Liver Injury*/prevention & control, Humans ; Animals ; Oxidative Stress/drug effects ; Antioxidants/therapeutic use ; Liver/drug effects ; Liver/pathology ; Liver/metabolism

Protective Role of Coenzyme Q10 Against Isoniazid and Rifampicin-Induced Hepatotoxicity in Rats via Modulation of PPAR-γ, iNOS, and NF-κB.

Autoren: B UL Mukherjee AG Sabina EP et al.

Quelle: Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2025 Nov; Vol. 39 (11), pp. e70585.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley Country of Publication: United States NLM ID: 9717231 Publication Model: Print Cited Medium: Internet ISSN: 1099-0461 (Electronic) Linking ISSN: 10956670 NLM ISO Abbreviation: J Biochem Mol Toxicol Subsets: MEDLINE

MeSH-Schlagworte: Ubiquinone*/analogs & derivatives , Ubiquinone*/pharmacology , Isoniazid*/toxicity , Isoniazid*/adverse effects , PPAR gamma*/metabolism , Rifampin*/toxicity , Rifampin*/adverse effects , NF-kappa B*/metabolism , Nitric Oxide Synthase Type II*/metabolism , Chemical and Drug Induced Liver Injury*/prevention & control , Chemical and Drug Induced Liver Injury*/metabolism , Chemical and Drug Induced Liver Injury*/pathology , Liver*/metabolism , Liver*/drug effects , Liver*/pathology, Animals ; Rats ; Male ; Rats, Wistar